<DOC>
	<DOCNO>NCT01176903</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Glycopyrrolate pMDI single repeat administration .</brief_summary>
	<brief_title>Safety Efficacy Study Glyco pMDI After Single Repeated Administration</brief_title>
	<detailed_description>The study divide two part : - Part 1 conduct accord single-centre , randomize , double-blind , placebo-controlled , single-dose escalation , alternate crossover design two group COPD patient . Treatments administer Part 1 ( SD1 , SD2 , SD3 , SD4 , SD5 , SP ) . The primary objective Part 1 evaluation safety tolerability Glyco single administration . - Part 2 conduct accord single-centre , randomize , double-blind , placebo-controlled , 4-period , 4-treatment , repeat dose cross-over design follow open-label extension period tiotropium . Treatments administer Part 2 ( MD1 , MD2 , MD3 , MP , Tiotropium ) . On last treatment day morning , Formoterol 12 µg administer patient top placebo Glyco Tiotropium . The primary objective Part 2 evaluation efficacy Glyco repeat administration . Part 2 start safety review result obtain Part 1 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Males females patient age 4075 year ; Written inform consent obtain ; Diagnosis moderatesevere COPD , accord GOLD guideline ; Current exsmokers smoke history ≥ 10 packyears Post bronchodilator FEV1 40 % 80 % predict value ( 40 % ≤ FEV1 &lt; 80 % ) , document screening visit ; Post bronchodilator FEV1/Forced Vital Capacity ( FEV1/FVC ) ≤ 0.70 ( absolute value ) document screen visit ; Airway reversibility least 100 mL within 30 45 minute inhalation ipratropium 80µg . History chronic seasonal allergy Blood eosinophil count 600 per µl Clinically relevant finding physical examination laboratory ECG parameter screen Occurrence clinically relevant abnormality 24h Holter ECG record screening ; Significant disease relate COPD ( eg . Myocardial infarction , stroke within precede 6 month ) ; Respiratory tract infection ( include upper tract ) 4 week prior study entry require change treatment ; Patients require oxygen therapy daily basis chronic hypoxemia ; History cystic fibrosis , bronchiectasis alpha1 antitrypsin deficiency , significant lung disease consider clinically significant investigator . Intolerance/hypersensitivity contraindication treatment M3 Antagonist excipients contain formulation use study . History alcohol substance abuse opinion Investigator may clinical significance . Patients treat slowrelease oral parental corticosteroid 8 week prior Screening Visit . Patients treat tiotropium 10 day prior Screening Visit ; Pregnant lactate woman female male subject willing use acceptable method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>